The IH recurrence rate was lower in the IPOM group by a clinically relevant but not statistically significant difference (4% vs. 9%; p¼0.58) CONCLUSIONS: In patients undergoing RALP and IH repair, IPOM repair is feasible, and may be associated with better perioperative outcomes and safety profile than suture repair. The effectiveness of IPOM repair was superior but not significantly. A prospective comparison against the gold-standard technique is warranted.
INTRODUCTION AND OBJECTIVES: Robot-assisted radical prostatectomy (RARP) has been reported to be associated with less incontinence than a retropubic radical prostatectomy (RRP) and laparoscopic radical prostatectomy (LRP); however, urinary continence continues to occur at a constant rate. There are few reports of urinary incontinence following a RARP to perform a detailed examination of the impact on the patients' postoperative quality of life (QOL) . Therefore, in this study, we examined the association between health-related QOL and urinary continence following RARP.
METHODS: From October 2010 to August 2016, 319 patients underwent RARP at our hospital. An SF-8 evaluation was performed for 154 retrospectively selected patients with observable data for 24 months (preoperative, and postoperative 1, 3, 6, 9, 12 , and 24-month evaluations) for our analysis. Evaluation items: physical function (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), mental health (MH), physical component summary (PCS), and mental component summary (MCS) were compared before and after surgery. In addition, "pad free" was defined as no incontinence, and we examined the relationship between the postoperative urinary continence and SF-8 data.
RESULTS: The average age at surgery was 65 (range: 48e76) years, the average preoperative PSA was 9.16 ng/mL (range: 1.17e35.4), and the average prostate volume was 31.6 mL (range: 11e131). We observed a significant reduction at one month post-surgery compared with the preoperative values for all of the scores (all p < 0.0001), and the values recovered to the preoperative status between 3 and 12 months after surgery. The BP, GH, RE, MH and MCS were significantly increased compared with the preoperative values (BP: after nine months; GH: after nine months; RE: after 18 months; MH: after three months; and, MCS: at 12 months). For the group that achieved a pad-free status, the GH, VT, SF, and MH were significantly higher compared to those in the non-achievement group one month after surgery. Moreover, the RF, RP, RE, and MCS were significantly higher in the pad-free achieving group after three months after surgery. Significant differences in BP were not recognized after surgery between the two groups.
CONCLUSIONS: Although all of the scores significantly decreased within one month post-surgery, the values recovered to the preoperative score within 12 months. No urinary continence after surgery appears to be associated with a favorable recovery of patient QOL following RARP.
Source of Funding: none

MP97-19 SURGICAL OUTCOMES IN THE MANAGEMENT OF HIGH RISK PROSTATE CANCER USING THE SURGICAL OUTCOMES FOR ADVANCED PROSTATE CANCER SCORE
John Francis*, Simon Kim, Cleveland, OH; Hui Zhu, Cleveland , OH; Robert Abouassaly, Cleveland, OH INTRODUCTION AND OBJECTIVES: Principles of high quality oncologic surgery suggest that complete excision be achieved with negative surgical margins and adequate staging. Obtaining quality outcomes in Radical prostatectomy (RP) for high risk prostate cancer can be difficult given the increased risk of extra-prostatic extension and inability to directly visualize the disease intra-operatively. Little is known about the clinical predictors of a quality surgical outcome in patients with high risk prostate cancer. We hypothesize that higher volume providers have improved surgical outcomes.
METHODS: Patients diagnosed with prostate cancer were selected from the National Cancer Database between 2010-2013. Patients with biopsy Gleason sum 8 or PSA > 20 and no clinical evidence of metastasis were included for analysis. A Surgical Outcomes for Advanced Prostate cancer (SOAP) score was generated for each patient. Patients received 2 points each for negative surgical margins and sampling of 5 pelvic lymph nodes and 1 point each for no readmission with in 30 days, no mortality within 30 days, and hospital length of stay 2 days. Patients were considered to have a good surgical outcome with a SOAP score 6. Provider volume was e1310 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 calculated by number of RPs reported from the treatment facility with high volume centers considered to be ones in the top third of reported RPs. Multivariable logistic regression was conducted to determine factors independently associated with quality surgical outcomes using the SOAP score. RESULTS: We identified 72,864 patients with high risk disease, of whom 42.5% (n¼31,008) were treated with RP. Overall, 34.1% of patients had a quality surgical outcome with a SOAP score 6. On multivariable logistical regression, factors associated with a quality surgical outcome included surgery at a high volume center (OR 1.8: CI 1.6-1.9; p¼ <0.01), surgery at an academic hospital (OR 1.8: CI 1.7-1.9: p¼ <0.01), cN1 stage (OR 1.6: CI 1.2-2.0; p¼ <0.01), and omission of neoadjuvent hormonal therapy (OR 1.4: CI 1.3-1.5; p¼ <0.01). Factors associated with a poor surgical outcome include robotic approach (OR 0.81: CI 0.76-0.87; p¼ <0.01), PSA > 30 (OR 0.59: CI 0.55-0.64; p¼ <0.01), and African American ethnicity (OR 0.89: CI 0.82-0.96; p¼ <0.01).
CONCLUSIONS: For patients with high risk prostate cancer, treatment at high volume centers and at academic centers appear to be associated with a high quality surgical outcomes. Given the increased use of this management strategy, optimizing surgical quality is needed in order to achieve the best outcomes for this aggressive malignancy.
Source of Funding: None
MP97-20 PREDICTION OF NON-BIOCHEMICAL RECURRENCE RATE AFTER ROBOT ASSISTED RADICAL PROSTATECTOMY (RARP) IN A JAPANESE COHORT: DEVELOPMENT OF A POSTOPERATIVE NOMOGRAM
Kazuki Hasama*, Makoto Ohori, Yosuke Hirasawa, Tatsuo Gondo, Go Nagao, Takashi Mima, Takeshi Kashima, Yoshihiro Nakagami, Yoshio Ono, Kazunori Namiki, Rie Inoue, Takashi Nagao, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Previously, we developed the postoperative nomogram to predict the non-biochemical recurrence in patients with open and RARP (IJU 21:479, 2014) . However, we found the significant differences of pathological and prognostic outcomes between open and RARP (AUA2016 Hirasawa). Therefore, we up-dated and developed the postoperative nomogram to predict the non-biochemical recurrence rate using the Japanese patients treated with RARP.
METHODS: A total of 1000 Japanese patients with T1-3N0M0 prostate cancer who underwent RARP and pelvic lymph node dissection at Tokyo Medical University hospital from 2009 to 2015 were studied. Patients with neoadjuvant therapy were excluded. A nomogram was constructed based on Cox hazard regression analysis evaluating the prognostic significance of serum PSA and pathological factors in the RARP specimens. The discriminating ability of the nomogram was assessed by the concordance index (C-index), and the predicted and actual outcomes were compared with a bootstrapped calibration plot.
RESULTS: With a mean follow up of 32.0 months, a total of 145 patients (14.5%) experienced biochemical recurrence with a 5-year non-biochemical recurrence rate of 80.0%. A Cox hazard regression analysis showed that preoperative PSA (p<0.0005), prostatectomy Gleason score (p<0.0005), pathological stage (p¼0.001), surgical margins (p<0.0005), and lymphovascular invasion (p¼0.0024) were significant factor to predict biochemical recurrence. Based on this analysis, a nomogram was constructed to predict non-biochemical recurrence using PSA level and pathological features in RARP specimens. The concordance index was 0.80, and the calibration plots appeared to be accurate.
CONCLUSIONS: Since RARP became most popular procedure in Japan, our postoperative nomogram can provide valuable information to many patients regarding the need for adjuvant/salvage radiation or hormonal therapy after RARP. To our knowledge, our nomogram may be the first nomogram for the non-Caucasian Asian population who were treated with RARP Source of Funding: none 
INTRODUCTION AND OBJECTIVES:
The programmed cell death-1 (PD-1) pathway has been suggested to play an important role in tumor immune escape. We evaluated the change of PD-1 expression before and after BCG therapy and its prognostic significance in nonmuscle invasive bladder cancer (NMIBC) patients.
METHODS: We evaluated 78 matched tissue samples of NMIBC in both previous tumors before BCG therapy and BCG-relapsing tumors, which was defined as recurrence after achieving a disease-free status by initial BCG instillations for 6 months. We counted PD-1 positive tumors infiltrating lymphocytes under x200 magnification immunohistochemically and when the number of PD-1 positive cells was more than 18, PD-1 expression was defined as high.
RESULTS: The median follow-up interval after BCG relapse was 81 months. The median number of PD-1 positive cells in previous tumors just before BCG therapy was 3.5, which was significantly lower than that in BCGrelapsing tumors (17.0, p<0.001). High PD-1 expression was observed in 20 previous tumors just before BCG therapy (25.6%) and 36 BCG-relapsing tumors (46.2%). An increase in PD-1 expression after BCG therapy was observed in 52 cases (66.6%, Figure A) . After excluding 10 muscle invasive bladder cancers at the time of BCG-relapsing, subsequent stage progression was noted in 8 (11.8%). Kaplan-Meier curves showed that the 5-year progression-free survival rate was 74.1% in patients with PD-1 high expression in BCG-relapsing tumors, which was significantly lower than that in patients with PD-1 low expression (94.1%, p¼0.042, Figure B ). Multivariate Cox regression analysis showed that PD-1 high expression (HR¼8.27, p¼0.033) was an independent risk factor for stage progression.
CONCLUSIONS: PD-1 was induced by BCG therapy and PD-1 expression in BCG-relapsing tumor might be an important indicator for predicting stage progression in NMIBC.
